Huan Wang

Huan Wang

Auto-generated profile, based on publicly available information

Huan Wang

Department of Radiology, The First Affiliated Hospital of Xi’an Jiaotong University, 710061 Xi’an, Shaanxi, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
HWHuan Wang
Huan Wang
JGJianxin Guo
Jianxin Guo
TWTianze Wang
Tianze Wang
KWKai Wang
Kai Wang
ZWZhuojun Wu
Zhuojun Wu
TSTianze Sun
Tianze Sun
Objective To assess the efficacy and safety of bevacizumab (BEV) in patients with glioma. Design Systematic review and meta-analysis. Participants Adults aged 18 years and above, whose histology was confirmed to be malignant glioma. Primary and secondary outcome measures The main indicators included progression-free survival (PFS) rate and overall survival (OS) rate, and the secondary indicators were adverse reactions. Results A total of 11 clinical centre trials were included in this study for meta-analysis, including 2392 patients. The results of the meta-analysis showed that the median PFS rate of the BEV group was significantly higher than that of the non-BEV group (p<0.00001). When comparing PFS between two groups, we found that the PFS in the BEV group was higher than that in the non-BEV group at 6 months (OR 3.31, 95% CI 2.74 to 4.00, p<0.00001), 12 months (OR 2.05, 95% CI 1.70 to 2.49, p<0.00001) and 18 months (OR 1.31, 95% CI 1.02 to 1.69, p=0.03). But at 24 months (OR 0.83, 95% CI 0.50 to 1.37, p=0.47), there was no significant difference between the two groups. At 30 months (OR 0.62, 95% CI 0.39 to 0.97, p=0.04), the PFS of the BEV group was lower than that of the non-BEV group. Moreover, The results showed that BEV had no significant effect on improving OS, but the adverse reaction in BEV group was significantly higher than that in non-BEV group. Conclusion The evidence suggests that BEV can significantly prolong the PFS of patients with glioma within 18 months and shorten the PFS of patients after 30 months. This limitation may be related to the subgroup of patients, the change of recurrence mode, the optimal dose of drug, the increase of hypoxia, the enhancement of invasiveness and so on. Therefore, it is necessary to carry out more samples and higher quality large-scale research in the future.

28 October 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
HWHuan Wang
Huan Wang
TWTianze Wang
Tianze Wang
MTManyun Tang
Manyun Tang
PDPeizhu Dang
Peizhu Dang
CZChangying Zhao
Changying Zhao
JGJianxin Guo
Jianxin Guo
Background: Atrial fibrillation (AF) can increase the risk of stroke by five-fold; strokes associated with AF are more likely to lead to death or severe disability in patients. Thus, preventing the formation of thrombosis is of vital importance in the treatment of patients with AF. Epicardial adipose tissue (EAT) is a risk factor for AF and is closely associated with many AF-related complications. However, to our knowledge, no in-depth studies on the relationship between the incidence of thrombosis in AF patients and EAT have been conducted. Therefore, it is of great clinical significance to explore the potential of EAT quantification in predicting intra-atrial thrombosis in patients with AF. Methods: This is a case–control study; patients with AF who underwent coronary computed tomography angiography (CCTA) were included. These patients were divided into the thrombus group and the non-thrombus group according to the results of transesophageal echocardiography (TEE). The volume of EAT, the mean density of EAT, and the ratio of EAT volume to the whole heart volume were measured by CCTA, and the data of the two groups were compared. Meanwhile, the diagnostic efficiency of using these parameters was analyzed. Result: A total of 308 patients with AF who underwent both TEE and CCTA were enrolled in this study. After a 1:1 propensity score matching (PSM) analysis based on age and sex, a total of 76 patients were finally included. Compared with the patients in the non-thrombus group, those in the thrombus group had a larger volume of EAT (132.38 ± 45.25 cm3 vs. 95.51 ± 25.38 cm3; p < 0.001) and a higher ratio of EAT volume to the whole heart volume (0.13 ± 0.05 vs. 0.10 ± 0.03; p < 0.05). However, there was no difference in the mean density of EAT between the two groups. The volume of EAT was identified as an independent risk factor (odds ratio = 1.042; p = 0.003). Moreover, the receiver operating characteristic (ROC) analysis presented the EAT volume as a potential diagnostic value in predicting intra-atrial thrombus in AF patients, with an area under the curve (AUC) of 0.755. Conclusions: The EAT volume may be a potential biomarker for predicting intra-atrial thrombosis in patients with AF; however, further validation is required to confirm the diagnostic value.